The introduction of androgen-receptor pathway inhibitors (ARPIs), including abiraterone acetate, apalutamide, darolutamide, and enzalutamide has significantly transformed the treatment landscape for advanced/metastatic prostate cancer (PCa) based on definitive survival benefits when added to androgen deprivation therapy (ADT) [1, 2]. Here, AR is linked to metastatic prostate carcinoma.